Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its ...

The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed prices of 80 new drugs including anti-diabetes, anti-hypertension, pain relief formulations from major pharmaceutical companies, in its ...

OK, I know my gig is positivity and being upbeat and all that, but for today I thought I’d rant on about something that irks ...

It could also help it keep pace with rival drugs in the SGLT2 inhibitor class as competition gets more intense. Last year, Jardiance achieved encouraging results in the EMPA-REG OUTCOME trial ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

A new analysis presented at the ACC 2025 meeting also finds that the new prices for heart failure drugs negotiated through Medicare will reduce hospitalizations. More Medicare Part D patients will ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

Eli Lilly and Company, Corcept Therapeutics, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks represent the publicly ...